A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis
Launched by FERRING PHARMACEUTICALS · Feb 7, 2024
Trial Information
Current as of June 17, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject aged ≥18 at screening
- • Established diagnosis of ulcerative colitis by standard clinical, endoscopic and histological criteria, for more than 3 months at screening
- Exclusion Criteria:
- • Active disease or history of Crohn's disease
- • Active disease or history of irritable bowel syndrome (IBS) or any other chronic intestinal disease apart from UC
- • Active gastrointestinal infection.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a global biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies that address unmet medical needs in various therapeutic areas, including reproductive health, urology, and gastrointestinal disorders. With a strong commitment to advancing healthcare through scientific excellence and patient-centered solutions, Ferring leverages its extensive expertise in hormone-related treatments and personalized medicine. The company actively engages in clinical research to develop safe and effective therapies, striving to improve the quality of life for patients worldwide while maintaining a focus on ethical practices and collaboration in the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
North Little Rock, Arkansas, United States
Shreveport, Louisiana, United States
Hamden, Connecticut, United States
Oklahoma City, Oklahoma, United States
Glenview, Illinois, United States
Gurnee, Illinois, United States
Jacksonville, Florida, United States
Inverness, Florida, United States
Orange City, Florida, United States
Patients applied
Trial Officials
Global Clinical Compliance
Study Director
Ferring Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported